CPHI Online Trend Report: How can flow chemistry help businesses achieve their sustainability goals?
In our latest CPHI Online Trend Report, we partner with Asymchem to understand the innovative potential of flow chemistry for API manufacturing, especially in regards to meeting sustainability goals.
With insight from industry leaders, academia, and more, this free report gives an in-depth examination of the principles behind flow chemistry, the core tenets of Green Chemistry, and how API manufacturing can maximise the potential of flow technologies in their operations.
Active pharmaceutical ingredients (APIs) form the therapeutic base of almost all drug products. Whether they are small molecule synthetic drugs or biologics derived from human, animal, or microorganism biotechnology, the manufacturing of APIs involves a diverse range of complex chemical and/or biological processes. There are a number of aspects to consider regardless of the type of API, as Jon Brice, Senior Vice President of Business Development at Asymchem Group, comments in the report: “Irrespective of the operational motif, the considerations remain the same – control of impurities, a robust process that can be validated, tracking and quantifying impurities, and collecting data on process parameters.”
Key drivers of API research and manufacturing are in the form of oncology drugs, novel formulations in targeted therapies, and the rise in obesity drugs. One of the most pressing issues for API manufacturers, however, remains balancing sustainability concerns with the safety, quality, and economic viability of their drug products. At each stage of API manufacturing, various solvents, chemicals, and waste products are used and/or produced resulting in a process that is energy and material-intensive. While sustainable operations tend to focus on improving waste reduction, energy efficiency, and greener solvents, there remain untapped opportunities in optimising reaction conditions, reducing the environmental impact of raw materials, and enhancing the overall efficiency of chemical processes, as Senior Scientist at Fraunhofer IMM Gabriele Menges-Flanagan states.
Flow chemistry technologies may be the next transformational technology manufacturers can take advantage of. Such enhancements to operations include improved control over heat and mass transfer, generation and consumption of reactive intermediates in a safer manner, less impurities generated, and improved overall yields. Flow chemistry is also very versatile and flexible with room to be optimised for the reaction taking place. However, some challenges remain for the full adoption of flow technologies in pharmaceutical manufacturing – namely, worker expertise and know-how, as well as regulatory issues around manufacturing practices for flow.
Despite these continuing challenges, experts agree that flow chemistry can offer a number of benefits for API manufacturing, especially in regards to achieving sustainability goals. “You can expand the scope of such a technology, but the real advantage with flow is using it where appropriate and optimising it to a specific problem,” Brice concludes.
To find out more about how flow chemistry can support sustainable API manufacturing, download our FREE Trend Report and gain access to leading industry insight.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...